Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. (Q50856151)
Jump to navigation
Jump to search
scientific article published in August 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. |
scientific article published in August 2013 |
Statements
Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer. (English)
1 reference
Andrew D Seidman
1 reference
Alison K Conlin
1 reference
Ariadne Bach
1 reference
Mary Ellen Moynahan
1 reference
Diana Lake
1 reference
Andres Forero
1 reference
Gail Shaw Wright
1 reference
Mary Helen Hackney
1 reference
Alicia Clawson
1 reference
Clifford A Hudis
1 reference
1 August 2013
1 reference
13
1 reference
4
1 reference
239-246.e1
1 reference